Business Wire

NY-IFF

Share
IFF Named to Barron’s 100 Most Sustainable Companies List for Third Consecutive Year

Regulatory News:

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced its third consecutive recognition on Barron’s 100 Most Sustainable Companies List, an index first launched in February 2018. It joins the ranks of 99 other leading U.S. companies assessed for environmental, social and corporate governance practices.

“We are delighted to once again be named to Barron’s prestigious sustainability index,” said Andreas Fibig, IFF Chairman & CEO. “This recognition is further testament to our passionate employees across the world and IFF’s commitment to global sustainability leadership, as we redefine how we live in and care for the resources of our world.”

In partnership with U.S. based investment advisory firm Calvert Research and Management, the Barron’s list was compiled by evaluating the 1000 largest publicly traded companies against hundreds of ESG performance indicators. These indicators, which address topics such as workplace diversity, data security and greenhouse-gas emissions, were then used to rank each company’s performance in five key constituencies: shareholders, employees, customers, community and the planet.

IFF’s EVP, Chief Global Scientific & Sustainability Officer Dr. Gregory Yep said, “This is a fantastic achievement for IFF, where sustainability priorities remain deeply connected to the overall success of our organization. As IFF continues to grow and evolve, we remain focused on opportunities to create a smarter, greener and more viable company positioned to protect our planet and the well-being of future generations.”

Through 2019, the Company:

  • Continues to execute on its environmental goals focused on emission reductions, zero waste to landfill and water stewardship, known collectively as “EcoEffective+”
  • Signed the United Nations’ “Business Ambition for 1.5°C – Our Only Future” pledge, a campaign to put more aggressive science-based goals into action to help limit global temperature rise to 1.5 degrees Celsius
  • Received Double-A distinction from CDP, including recognition on CDP’s A List for Climate Change (fifth consecutive) and Water Security (second consecutive), reaffirming IFF’s global leadership in environmental responsibility
  • Opened the industry’s largest solar array at its Union Beach, New Jersey property, which is expected to generate over nine million kilowatt hours annually, powering IFF’s R&D facility and returning any excess energy to the grid
  • Deepened its commitment to diversity and inclusion by signing onto the United Nations Global LGBTI Standards of Conduct for Business (“the Standards”), joining 250 of the world’s largest companies in the pledge to tackle discrimination against lesbian, gay, bisexual, transsexual and intersex (LGBTI) people in the community, workplace and marketplace
  • Solidified its commitment to gender parity and women’s empowerment by pledging to adopt the United Nations Women’s Empowerment Principles (“the Principles”), a set of seven tenets to advance and empower women and provide equal treatment in the workplace, marketplace and community
  • Received the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing ESG data, benchmarks and ratings, for the Company’s top-scoring performance in economic, social and environmental categories
  • Pledged to achieve a full global EDGE certification in 2020, to advance the Company’s certification from the Economic Dividends for Gender Equality (EDGE) for its business in the United States
  • Installed a series of nesting platforms to support the conservation of ospreys, a North American raptor species challenged by environmental changes

For more information on sustainability at IFF, visit https://www.iff.com/en/our-purpose/sustainability .

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye